SSI(SZ:002742)2022-12-04 10:22Group 1: Company Overview and Strategy - The company aims to strengthen and optimize its first industry in building materials and chemicals while significantly developing its second industry in pharmaceuticals [3] - Ethiopia is chosen for investment due to its political stability, strategic partnership with China, and a population of over 90 million, presenting substantial development potential [3] - The company plans to follow the national strategy of "going global" and enhance investments in building materials and pharmaceuticals in Ethiopia [4] Group 2: Financial Performance and Projections - The gross profit margin for the building materials project is approximately 40%, while the pharmaceutical project has not yet commenced production, but is expected to have a considerable gross profit margin [4] - The company expresses confidence in its 2018 operational outlook, despite recent increases in cement prices due to environmental pressures and capacity restrictions [5] Group 3: Investment and Development Plans - The company is focusing on building a complete pharmaceutical manufacturing chain, including intermediates, raw materials, and formulations, while integrating international strategies [5] - A professional pharmaceutical management team and research center have been established to enhance resource integration and internal management [5] Group 4: Stakeholder Engagement and Future Initiatives - The company is considering implementing an equity incentive plan to enhance team cohesion and is exploring various methods for this initiative [6] - The chairman of the company expresses strong confidence in the future development strategy, supporting sustainable and healthy growth [6]